Zobrazeno 1 - 10
of 224
pro vyhledávání: '"Sophie Postel Vinay"'
Autor:
Clémence Astier, Carine Ngo, Léo Colmet-Daage, Virginie Marty, Olivia Bawa, Claudio Nicotra, Maud Ngo-Camus, Antoine Italiano, Christophe Massard, Jean-Yves Scoazec, Cristina Smolenschi, Michel Ducreux, Antoine Hollebecque, Sophie Postel-Vinay
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-6 (2024)
Abstract Biliary tract cancers (BTCs) are heterogeneous malignancies with dismal prognosis due to tumor aggressiveness and poor response to limited current therapeutic options. Tumor exome profiling has allowed to successfully establish targeted ther
Externí odkaz:
https://doaj.org/article/0e99e403d1d04ae1bc389c998b7b3798
Autor:
Jean-Pierre Armand, Marie-Priscille Brun, Janine Cossy, Joël Doré, Philippe Duchateau, Gérard Guillamot, Jean-François Haeuw, Patricia Melnyk, Alexandre Pachot, Sophie Postel-Vinay, Raphaël Rodriguez, Nathalie Strub-Wourgaft, Bruno Villoutreix, Bernard Meunier
Acteurs ou bénéficiaires, nous sommes tous spectateurs sidérés de l'ampleur des progrès de la médecine. Ils sont la conséquence des découvertes du XXe siècle, en particulier sur la biologie moléculaire et le génome. La recherche du XXIe si
Autor:
Capucine Baldini, Francois-Xavier Danlos, Andreea Varga, Matthieu Texier, Heloise Halse, Severine Mouraud, Lydie Cassard, Stéphane Champiat, Nicolas Signolle, Perrine Vuagnat, Patricia Martin-Romano, Jean-Marie Michot, Rastislav Bahleda, Anas Gazzah, Lisa Boselli, Delphine Bredel, Jonathan Grivel, Chifaou Mohamed-Djalim, Guillaume Escriou, Laetitia Grynszpan, Amelie Bigorgne, Saloomeh Rafie, Alae Abbassi, Vincent Ribrag, Sophie Postel-Vinay, Antoine Hollebecque, Sandrine Susini, Siham Farhane, Ludovic Lacroix, Aurelien Parpaleix, Salim Laghouati, Laurence Zitvogel, Julien Adam, Nathalie Chaput, Jean-Charles Soria, Christophe Massard, Aurelien Marabelle
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-14 (2022)
Abstract Background We aimed to determine the safety and efficacy of nintedanib, an oral anti-angiogenic tyrosine kinase inhibitor, in combination with pembrolizumab, an anti-PD1 immunotherapy, in patients with advanced solid tumors (PEMBIB trial; NC
Externí odkaz:
https://doaj.org/article/cc022ab82e6e4fd69d684a17c4dfa3ff
Autor:
Stephane Champiat, Aurélien Marabelle, Anna Spreafico, Mehmet Altan, Todd M Bauer, Osama Rahma, Karen A Autio, Neeta Somaiah, Meredith McKean, Aaron R Hansen, Jan H M Schellens, Willeke Ros, F Stephen Hodi, Jeffrey S Weber, John V Heymach, Herbert Struemper, Sandrine Aspeslagh, Daniel C Cho, Jennifer K Litton, Axel Hoos, Vincent K Lam, Emmett V Schmidt, Sophie Postel-Vinay, Frans L Opdam, Elaine M Paul, Christoph M Ahlers, Helen Zhou, Shelby A Gorman, Maura Watmuff, Kaitlin M Yablonski, Niranjan Yanamandra, Michael J Chisamore
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Background The phase I first-in-human study ENGAGE-1 evaluated the humanized IgG1 OX40 agonistic monoclonal antibody GSK3174998 alone (Part 1 (P1)) or in combination with pembrolizumab (Part 2 (P2)) in patients with advanced solid tumors.Methods GSK3
Externí odkaz:
https://doaj.org/article/cede222f65c649b89ade485245fc9ae7
Le VEGF (vascular endothelial growth factor) est responsable de nombreux effets sur la vascularisation tumorale, notamment la prolifération des cellules endothéliales, la migration, l'invasion, la perméabilité vasculaire et vasodilatation ou enco
Autor:
Patricia Martin‐Romano, Eduardo Castanon, Samy Ammari, Stéphane Champiat, Antoine Hollebecque, Sophie Postel‐Vinay, Capucine Baldini, Andrea Varga, Jean Marie Michot, Perrine Vuagnat, Aurélien Marabelle, Jean‐Charles Soria, Charles Ferté, Christophe Massard
Publikováno v:
Cancer Medicine, Vol 9, Iss 8, Pp 2643-2652 (2020)
Abstract Background PD(L)1 antibodies (anti‐PD(L)‐1) have been a major breakthrough in several types of cancer. Novel patterns of response and progression have been described with anti‐PD(L)‐1. We aimed at characterizing pseudoprogression (PS
Externí odkaz:
https://doaj.org/article/a4e7a1041c934bc3942c24fc39614624
Autor:
Emily Alouani, Anas Gazzah, Sandrine Mercier, Ratislav Bahleda, Antoine Hollebecque, Jean-Marie Michot, Capucine Baldini, Samy Ammari, Stephane Champiat, Aurelien Marabelle, Sophie Postel-Vinay, Vincent Ribrag, Yohann Loriot, Santiago Ponce Aix, Linda Mahjoubi
Publikováno v:
European Journal of Cancer. 188:1-7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64a7c81162b4ec55e98b55099563639d
https://doi.org/10.1016/j.ejca.2023.04.006
https://doi.org/10.1016/j.ejca.2023.04.006
Publikováno v:
Molecular & Cellular Oncology, Vol 6, Iss 2, Pp 1-4 (2019)
Loss of excision repair cross-complementation group 1 (ERCC1), frequently found in lung cancer, and mutations in breast cancer type 1/2 susceptibility genes (BRCA1/2), often found in ovarian, breast and prostate cancers, confer sensitivity to poly-(A
Externí odkaz:
https://doaj.org/article/d47bb605b76545a88a86206288006b5b
Autor:
Antoine Campagne, Ming-Kang Lee, Dina Zielinski, Audrey Michaud, Stéphanie Le Corre, Florent Dingli, Hong Chen, Lara Z. Shahidian, Ivaylo Vassilev, Nicolas Servant, Damarys Loew, Eric Pasmant, Sophie Postel-Vinay, Michel Wassef, Raphaël Margueron
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-15 (2019)
In Drosophila, the Calypso–ASX complex catalyzes H2A deubiquitination and aids Polycomb in transcriptional silencing. Here the authors show that the orthologous complex, BAP1.com, promotes gene activation by counteracting PRC1-mediated gene silenci
Externí odkaz:
https://doaj.org/article/92338fdb37b04b3b97a5b2deb5e4d404
Autor:
Lauren Seknazi, Arthur Geraud, Vincent Goldschmidt, Capucine Baldini, Stéphane Champiat, Christophe Massard, Sophie Postel-Vinay, Aurelien Marabelle, Rastilav Bahleda, Antoine Hollebecque, Cristina Smolenschi, Anas Gazzah, Jean-Marie Michot, Patricia Martin-Romano, Aurore Vozy, Perrine Vuagnat, François-Xavier Danlos, Arnaud Bayle, Linda Mahjoubi, Barbara Pistilli, Yohann Loriot, Santiago Ponce-Aix, Kaissa Ouali
Publikováno v:
Cancer Research. 83:P2-13
Background: Breast cancer (BC) is the most frequent cancer and the second leading cause of cancer death for women. Although there is a need of new treatments to improve BC outcome, patients with BC are still under-represented in early phase trials, p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf3c7ec9e4e98d11575b6815653da494
https://doi.org/10.1158/1538-7445.sabcs22-p2-13-02
https://doi.org/10.1158/1538-7445.sabcs22-p2-13-02